Auto Summaries

Last updated: 2024 Oct 18

Total hit(s): 5413

S.No.
1	39321502	Corrigendum to "The significance of recurrent de novo amino acid substitutions that emerged during chronic SARS-CoV-2 infection: an observational study" [eBioMedicine, 2024;107:105273].	N/A	EBioMedicine	2024 Oct	6.49	1
2	39083043	Features of the SARS-CoV-2 KP.3 variant mutations.	N/A	Infect Dis (Lond)	2024 Jul 31	1.23	1
3	38961696	Is there an increased number of community-acquired pneumonia requiring drainage placement in children after COVID-19 pandemic in Italy?	N/A	Pediatr Pulmonol	2024 Jul 3	2.64	1
4	39030295	Deletion of V483 in the spike confers evolutionary advantage on SARS-CoV-2 for human adaptation and host-range expansion after a prolonged pandemic.	N/A	Cell Res	2024 Jul 19	10.9	1
5	38809158	Another variant another history: description of the SARS-CoV-2 KP.2 (JN.1.11.1.2) mutations.	N/A	Infect Dis (Lond)	2024 Jul	1.23	1
6	38664266	Correction: Detection of SARS-CoV-2 spike protein D614G mutation using muTGGE.	N/A	Mol Biol Rep	2024 Apr 25	2.19	1
7	38272241		N/A		2024 Apr		1
8	38048665	Fixation and reversion of mutations in the receptor-binding domain of SARS-CoV-2 spike protein.	N/A	Diagn Microbiol Infect Dis	2024 Feb	2.33	1
9	38219759	Characteristics of the SARS-CoV-2 omicron HK.3 variant harbouring the FLip substitution.	N/A	Lancet Microbe	2024 Jan 11	- n/a -	1
10	38224200	The roles of innate and adaptive immunity in inactivated viral vaccination-mediated protection against COVID-19.	N/A	Clin Transl Med	2024 Jan	4.08	1
11	38149407	No emergence of resistance mutations in COVID-19 patients receiving nirmatrelvir/ritonavir.	N/A	J Med Virol	2024 Jan	2.07	1
12	38164631	The mutation point of view of the SARS-CoV-2 HV.1 lineage.	N/A	J Med Virol	2024 Jan	2.07	1
13	38129796	Correction: Near complete genome sequences from Southern Vietnam revealed local features of genetic diversity and intergenerational changes in SARS- CoV-2 variants in 2020-2021.	N/A	BMC Infect Dis	2023 Dec 21	2.58	1
14	37186902	Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants.	SARS-CoV-2 causes significant morbidity and mortality in humans. One factor that may influence virus control is pre-existing immunity conferred by an individual's past exposures to endemic coronaviruses (eCOVIDs) The nations where continuous exposures to eCOVIs are very high due to religious and traditional causes showed significantly lower cases and low mortality rates per 100,000.	Libyan J Med	2023 Dec	2.8	1
15	36426608	Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses.	N/A	Emerg Microbes Infect	2023 Dec	5.84	1
16	36820816	The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection.	Anti-SARS-CoV-2S antibody levels were measured (ECLIA assay) in 50 healthcare workers with and without a history of COVID-19 infection to determine the humoral immune response to the third dose of the BNT162b2 vaccine. Age, gender, BMI, type work, type of work, and presence of comorbidities may be associated with different humoral immunizations. The results of this study can be used to improve the vaccination strategy for the general population.	Ann Med	2023 Dec	3.01	1
17	36715323	Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?	A test-negative case-control study was conducted among adults (age >/=18 years) who were at-risk for COVID-19 and presented for nasopharyngeal real-time polymerase chain reaction testing during the Omicron variant-dominant period in Thailand (1 January 2022-15 June 2022) The highest VE were observed in individuals receiving the 4-dose regimen,. preventing infection (65%) and preventing moderate-to-critical diseases (82%) The heterologous boosters with viral vector and mRNA vaccines were highly effective and can be used in individuals who previously received the primary series of inactivated vaccine.	Emerg Microbes Infect	2023 Dec	5.84	1
18	36715434	Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients.	Study aimed to identify adverse events following the first three doses of COVID-19 vaccines in hemodialysis patients. Overall, 79%, 50% and 84% of the participants experienced at least one adverse event after their first, second, and third doses. Age, sex, dialysis vascular access and vaccine types were associated with postvaccination adverse events.	Ren Fail	2023 Dec	1.68	1
19	36594480	COVID-19 vaccine hesitancy between family decision-makers and non-decision-makers among college teachers.	A cross-sectional online survey was administered across mainland China from 4 to 7 August 2021. Overall, 42.2% of the teachers were hesitant to being vaccinated against COVID-19. The hesitancy rate was lower among primary decision-makers than that among non-decision-makers. Those engaged in nursing education versus non-medical related professional education (OR = 2.67, 95% CI 1.29-5.49) were more likely to be hesitant.	Ann Med	2023 Dec	3.01	1
20	36788502	Novel COVID-19 vaccine hesitancy and acceptance, and associated factors, amongst medical students: a scoping review.	Medical students are likely to be exposed to COVID-19 patients so achieving high vaccination coverage rates for this group of healthcare workers is important. The aim of this scoping review was to evaluate the current literature to determine the rates of vaccine hesitancy and acceptance, and associated factors, amongst medical students.	Med Educ Online	2023 Dec	3.7	1
21	37114433	Mutations in SARS-CoV-2 variant nsp6 enhance type-I interferon antagonism.	A triple deletion (DeltaSGF or DeltaLSG) in nonstructural protein 6 augments nsp6-mediated antagonism of type-I interferon (IFN-I) signaling. The impact of mutations outside the Spike gene are poorly understood, but they may alter pathogenesis of SARS-CoV-2 variants in humans. Analyses of host responses from DeltaSGF-WA1-infected mice and primary airway cultures reveal activation of pathways indicative of a cytokine storm.	Emerg Microbes Infect	2023 Dec	5.84	1
22	37144395	Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation.	The main protease (3-chymotrypsin-like protease, 3CLpro) of SARS-CoV-2 has become a focus of anti-coronavirus research. Despite efforts, drug development targeting 3CLPro has been hampered by limitations in the currently available activity assays. Here, we report an orthogonal dual reporter-based gain-of-signal assay for measuring 3Clpro activity in living cells. This assay circumvents most limitations in previously reported assays, especially false positives caused by nonspecific compounds and signal interference from test compounds.	Emerg Microbes Infect	2023 Dec	5.84	1
23	37272331	An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults.	The neutralizing activity of the human serum after Omicron-based vaccine booster against different SARS-CoV-2 variants is poorly understood. We developed a dose updated vaccine (SCoK-Omicron) based on the RBD-Fc fusion protein vaccine and RBD domain of Omicrons BA.1.1. Further assays of single point mutations showed that K444T, L452R, N460K, or F486V was key mutations to cause immune evasion.	Emerg Microbes Infect	2023 Dec	5.84	1
24	37929659	Mutational analysis of severe acute respiratory syndrome coronavirus 2 in immunocompromised patients with persistent viral detection using whole genome sequencing.	N/A	Clin Transl Med	2023 Nov	4.08	1
25	37813112	Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand.	N/A	Lancet Infect Dis	2023 Oct 6	21.77	1